5.29

4.13% 0.21

After Hours: 5.61 0.32 +6.05%

Tscan Therapeutics Inc (TCRX)

Overview News Price History Financials Discussions Forecast

Tscan Therapeutics Inc stock is traded at $5.29, with a volume of 544.91K. It is up +4.13% in the last 24 hours and down -3.99% over the past month. TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Previous Close:

$5.08

Open:

$5.1

24h Volume:

544.91K

Relative Volume:

2.66

Market Cap:

$288.71M

Revenue:

$21.05M

Net Income/Loss:

$-89.22M

P/E Ratio:

-1.8304

EPS:

-2.89

Net Cash Flow:

$-64.50M

1W Performance:

+11.37%

1M Performance:

-3.99%

6M Performance:

-38.20%

1Y Performance:

+29.66%

1-Day Range:

$5.065

$5.98

1-Week Range:

$4.53

$5.98

52-Week Range:

$3.73

$9.69

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Name

Tscan Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (671)

Phone

857-399-9500

Address

880 WINTER STREET, WALTHAM

Employee

188

Twitter

Next Earnings Date

Latest SEC Filings

TCRX's Discussions on Twitter

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-16-24	Initiated	BTIG Research	Buy
May-13-24	Initiated	Needham	Buy
Jun-22-23	Initiated	Wedbush	Outperform

Tscan Therapeutics Inc Stock (TCRX) Latest News

09:17 AM

TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire

09:17 AM

09:15 AM

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - StockTitan

09:15 AM

04:52 AM

TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com India

04:52 AM

Nov 04, 2024

Waltham cancer biotech adds to real estate footprint - The Business Journals

Nov 04, 2024

TScan Therapeutics (NASDAQ:TCRX) Enters Second Amendment for Lease Agreement to Expand Operations at Winter Street FacilityOn October 28, 2024, TScan Therapeutics, Inc. finalized a second amendment to its lease agreement with PPF OFF 828-83 - Defense World

Nov 04, 2024

Oct 26, 2024

Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World

Oct 26, 2024

Oct 21, 2024

The Manufacturers Life Insurance Company Invests $90,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Oct 21, 2024

Oct 18, 2024

Where are the Opportunities in (TCRX) - Stock Traders Daily

Oct 18, 2024

Oct 15, 2024

BTIG Initiates Coverage of TScan Therapeutics (TCRX) with Buy Recommendation - MSN

Oct 15, 2024

Oct 08, 2024

Bank of Montreal Can Acquires Shares of 120,454 TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Oct 08, 2024

Bank of Montreal Can Invests $749,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Oct 08, 2024

Oct 06, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Lifted by Marshall Wace LLP - MarketBeat

Oct 06, 2024

Oct 05, 2024

American Century Companies Inc. Increases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Oct 05, 2024

Oct 04, 2024

TCRXTScan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 04, 2024

TScan Therapeutics Announces Upcoming Presentations at the - GlobeNewswire

Oct 04, 2024

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - StockTitan

Oct 04, 2024

Reviewing TScan Therapeutics (NASDAQ:TCRX) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World

Oct 04, 2024

Oct 01, 2024